About AdvanCell
AdvanCell is a Healthcare company based in Sydney (Australia) founded in 2019 by Andrew Adamovich. It operates as a radiopharmaceutical company developing targeted alpha therapies for cancer treatment. AdvanCell has raised $444.42 million across 5 funding rounds from investors including Abingworth, Department of Health, Disability and Ageing and SV Health Investors. Its chief executive is Andrew Adamovich. AdvanCell offers products and services including Alpha 212. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ADVANCELL ISOTOPES PTY LIMITED. Its competitors include Advanced Accelerator Applications, SOFIE, Mariana Oncology, Ariceum Therapeutics and Lantheus and 3 more; 7 of its 8 listed competitors have raised funding.
Company details
The company was founded in 2019 and is based in Sydney, Australia, within the radiopharmaceutical sector. Targeted alpha therapies for treating cancers including prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovarian types are developed. Operations center on a proprietary Pb production technology, which enables access to alpha isotopes for advancing clinical drug development.
- Headquarters Sydney, Australia
- Founders Andrew Adamovich
- SectorsHealthcare
- Phone•••• ••••
- Website advancell.com.au
- Social LinkedIn X
- Legal Name Advancell Isotopes Pty Limited
- Total Equity Funding$444.42M (USD)
in 5 rounds
- Latest Funding Round$315M (USD), Series D
Jun 2026
- InvestorsAbingworth
& 16 more
Products & Services of AdvanCell
AdvanCell offers a comprehensive portfolio of products and services, including Alpha 212.
Provides cGMP isotope for targeted alpha therapy in cancer treatment development.
Funding Insights of AdvanCell
AdvanCell has successfully raised a total of $444.42M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $315 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $444.42M
- Total Rounds 5
- Last Round Series D — $315M
- First Round $12.42M
(Aug 2022)
- Investors Count 17
All 5 funding rounds of AdvanCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $315M | Series D | – | Ally Bridge Group, Alpha Wave Global | |
| Apr 2025 | $18M | Grant | – | – | |
| Feb 2025 | $112M | Series C | – | SV Health Investors, Sanofi Ventures | |
| Dec 2023 | $5M | Series B | – | – | – |
| Aug 2022 | $12.42M | Series B | – | Morningside | – |
17 investors in total: 17 institutional.
Investors in AdvanCell
AdvanCell has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Abingworth, Department of Health, Disability and Ageing and SV Health Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on early-stage healthcare startups | – | svhealthinvestors.com | Boston, United States | |
Life-Sciences focused Early stage Corporate VC Firm investing in the US | – | sanofiventures.com | Paris, France | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Investments in healthcare companies are made by SymBiosis. | – | symbiosis.vc | Bentonville, United States | |
Multiple sectors are invested in by Morningside, a VC fund. | – | morningside.com | Newton, United States | |
Health technology investments are made by Tenmile in Australia. | – | tenmile.com | Perth, Australia | |
Early-stage medical companies are funded by this venture capital firm. | – | brandoncapital.vc | Melbourne, Australia | |
- | – | ally-bridge.com | - | |
- | – | alphawaveglobal.com | - | |
- | – | baincapitallifesciences.com | - |
Investor details for AdvanCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AdvanCell
11 people are tracked at AdvanCell (9 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Andrew Adamovich | Founder, CEO & Managing Director | Leadership |
Anna Karmann | Chief Medical Officer | Leadership |
Simon Puttick | CSO/COO | Leadership |
Gary Li | Chief Strategy Officer | Leadership |
Aimee Horsfall | VP Discovery | Leadership |
Paola Santoro | Vice President Clinical Development And Operations | Leadership |
Sheruna Naidoo | Vice President Technical Operations | Leadership |
Thien Dinh | Director Of Engineering | Leadership |
Julian F. Kelly | Chief Scientist (Nuclear & Chemical) | Leadership |
Kevin Kuan | SVP Technical Operations | Team |
Simranjeet Kaur | Research associate | Team |
Complete people profiles for AdvanCell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AdvanCell
3 dated milestones of AdvanCell across 7 years, from founding to its latest funding, stage changes and deals.
- Founded AdvanCell is founded.
- Funding First funding round of $12.4M.
- Funding Latest funding round, Series D, of $315.0M.
Competitors of AdvanCell
AdvanCell has 8 listed competitors in our database, 7 of them funded. They include Advanced Accelerator Applications, SOFIE, Mariana Oncology, Ariceum Therapeutics and Lantheus, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| sofie.com | 2008 | Culver, United States | $43.1M | 546 | Developer of molecular imaging systems and radio-pharmaceuticals | |
| marianaoncology.com | 2020 | Watertown, United States | $250M | 41 | Targeted radiopharmaceuticals for solid tumors are developed and pioneered. | |
| ariceum-therapeutics.com | 2021 | Berlin, Germany | $51.64M | – | Developer of drugs for systemic targeted radiation therapy to treat cancer | |
| lantheus.com | 2008 | Billerica, United States | – | 834 | Developer of diagnostic imaging agents and targeted therapeutics | |
| a9oncology.com | 2018 | Boston, United States | $261M | – | Radiopharmaceuticals for cancer treatment are developed using peptide-based technologies. | |
| artbio.com | 2021 | Sacramento, United States | $245.3M | – | Alpha radioligand therapies for cancer are developed using lead-212. | |
| pantera-life.com | 2022 | Mol, Belgium | $102.58M | – | Radiotheranostics using actinium-225 are developed for targeted cancer treatments. |
Detailed competitors of AdvanCell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AdvanCell
The website of AdvanCell (advancell.com.au) receives about 4.5K visits a month.
- Monthly visits4.5K
▲ 19.7% vs previous month
Top companies in Oncology
10 companies that operate in the same segment as AdvanCell (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Advancell
Complete news archive for AdvanCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AdvanCell
AdvanCell was founded in 2019 and raised its 1st funding round 3 years after it was founded.
AdvanCell is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Andrew Adamovich is the current CEO of AdvanCell. They have also founded this company.
AdvanCell is a funded company, having raised a total of $444.42M across 5 funding rounds to date. The company's 1st funding round was a Series B of $12.42M, raised on Aug 2022.
The company was founded in 2019 and is based in Sydney, Australia, within the radiopharmaceutical sector. Targeted alpha therapies for treating cancers including prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovarian types are developed. Operations center on a proprietary Pb production technology, which enables access to alpha isotopes for advancing clinical drug development.
AdvanCell's top competitors include Advanced Accelerator Applications, SOFIE and Mariana Oncology.
AdvanCell offers Alpha 212.
AdvanCell has 17 investors. Key investors include Abingworth, Department of Health, Disability and Ageing, SV Health Investors, Sanofi Ventures, and SymBiosis.
AdvanCell operates through Advancell Isotopes Pty Limited.